Bellerophon Completes Enrollment in Cohort 2 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Stock Information for Bellerophon Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.